What is GLP1?
GLP1 stands for glucagon-like peptide-1, a naturally occurring incretin hormone secreted in the gut when we eat. Its original evolutionary role is elegantly simple: help the body process nutrients, control appetite, and avoid glucose spikes. But in modern medicine, GLP1 has become the linchpin of a new era in obesity and diabetes care.
As soon as nutrients enter the small intestine, specialized L-cells release GLP1. This surge triggers a cascade: your pancreas increases insulin output (when glucose is present), suppresses unnecessary glucagon (which would otherwise raise blood sugar), and slows emptying of the stomach. The net result? Prolonged satiety and smoother, lower blood glucose peaks.
GLP1 Agonists: From Endocrinology to Clinics
Harnessing GLP1 pharmacologically was a breakthrough. Early GLP1 agonists like exenatide and liraglutide closely mimicked the body’s own hormone, but required daily or twice-daily dosing. Now, advanced drugs such as tirzepatide and semaglutide structurally amplify GLP1’s impact while also engaging additional pathways, allowing for potent, weekly injection regimens with sustained appetite reduction and metabolic improvements.
Weekly injection GLP1 therapies simplify adherence for patients and clinics. The combination of long-acting molecules and well-studied delivery devices has made these treatments accessible to many who previously struggled with daily medications.
The Dual Approach: GIP and GLP1 Together
While GLP1 is a superstar, the story is richer. New therapies like tirzepatide engage both GIP (glucose-dependent insulinotropic polypeptide) and GLP1 receptors. The dual agonist strategy leverages the synergy between these hormones, offering greater weight loss and metabolic benefits than GLP1 alone. Early trials suggest that patients achieve lower A1C, more substantial weight reduction, and improved energy regulation.
This approach is a direct result of decades of metabolic research. By targeting both receptors, tirzepatide can mimic the body’s own powerful post-meal hormonal response more completely, making it a meaningful leap forward in medical weight loss.
- GLP1 suppresses appetite and slows gastric emptying, reducing overeating.
- GIP enhances insulin secretion and promotes healthy fat distribution.
- Together, they reshape the body’s response to food and energy needs.
Real-World Impact: What Patients Experience
In clinical practice, GLP1-based medications consistently deliver meaningful outcomes. Patients commonly report a subdued sense of hunger, a newfound ability to walk past snacks, and significant progress when they pair treatment with lifestyle changes.
Weight loss of 10–20% of starting body weight is no longer rare. In my direct experience working alongside endocrinologists, patients on tirzepatide frequently achieve reduces cravings and sustained control, where diets alone failed. Side effects are real (see below), but GI symptoms usually fade, and many patients describe the benefits as “life-changing”.
- Reductions in fasting glucose and A1C (average: 1–2% drop).
- Consistent weight loss—often maintained for 12 months and beyond.
- Improved blood pressure and lipid profiles, reducing cardiovascular risk.
Risks and Considerations
GLP1 agonists such as those used in Mounjaro (tirzepatide) and other modern treatments are not for everyone. Common side effects include nausea, vomiting, and a feeling of fullness. Rare but serious risks (such as pancreatitis or gallbladder disease) have been documented, and patients with personal or family history of medullary thyroid carcinoma should avoid these medications.
- Start with low doses and titrate slowly to minimize GI effects.
- Inform your provider of any history of pancreatitis or thyroid issues.
- Monitor blood sugar if you have diabetes—hypoglycemia risk increases with other medications.
Trustworthy clinics guide patients through these risks with routine check-ins, structured prescription guidance, and accessible support lines.
Long-Term Outcomes and the Future of GLP1 Therapy
GLP1 therapies have moved from narrow diabetes management to broad obesity treatment and prevention of heart and kidney disease. Large studies (e.g., SURPASS, STEP) indicate durable results: sustained weight loss, lower risk of cardiac events, and a strong safety profile with ongoing monitoring.
As research grows, so does the potential for tailored protocols—combining GLP1 with exercise, nutrition, and behavioral support for individualized care plans. The future is not just weight loss, but comprehensive metabolic health.
For anyone considering GLP1-based therapy, the key is expert guidance. Seek clinicians who specialize in metabolic medicine and demand transparent discussion of benefits and risks. The science is strong, but the best results come from personalizing the approach to your unique physiology and goals.